查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1726299

全球基因療法起始材料市場：市場規模、佔有率、趨勢分析（按產品、開發階段、應用、最終用途和地區）、細分市場預測（2025-2030 年）

Gene Therapy Starting Materials Market Size, Share & Trends Analysis Report By Product (Viral Vectors, Plasmid DNA, Cell Lines), By Development Stage, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

基因治療起始材料市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球基因治療起始材料市場預計到2030年將達到54億美元，2025年至2030年期間的複合年成長率為19.24%。

這一成長是由對高品質原料不斷成長的需求推動的，這些原料旨在支持針對罕見疾病、遺傳疾病、癌症和其他複雜疾病的基因療法的不斷成長。隨著越來越多的治療方法通過臨床試驗並獲得監管部門的核准，對可擴展、符合 GMP 的質體、病毒載體和其他關鍵投入的需求持續成長。

此外，技術進步、研發投入的增加以及法律規範也進一步推動了市場的發展。此外，生物技術公司和製造商之間的合作旨在提高生產能力並確保供應鏈的一致性，這將使基因治療起始材料產業在整個預測期內實現強勁而持續的成長。

COVID-19 疫情凸顯了快速治療開發和可擴展製造的必要性，進一步加速了對基因治療起始材料的需求。這刺激了對先進生物生產基礎設施的投資，增加了對基因平台的關注，並刺激了質體DNA、病毒載體以及用於疫苗和基因療法開發的其他關鍵組件的成長。

此外，不斷擴大的基因治療管道也推動了市場的成長。隨著越來越多的治療方法通過臨床試驗並獲得監管部門的核准，對質體DNA 和病毒載體等高品質起始材料的需求持續增加。這導致對製造能力、先進技術和戰略夥伴關係的投資增加，以實現高效的擴大規模和供應，滿足世界各地基因治療開發商不斷變化的需求。

然而，圍繞安全、品質和合規性的嚴格監管要求可能會減緩基因治療產品的開發和核准。雖然這些規定對於確保患者安全至關重要，但它們通常涉及複雜的文件、大量的測試和漫長的審查時間。這會減緩市場進入速度、增加營運成本，並為缺乏監管專業知識的小型公司設置障礙。隨著產業的發展，滿足這些要求對於基因治療起始材料市場的相關人員來說仍然是一個重大挑戰。

基因治療起始材料市場報告重點

  • 病毒載體領域憑藉其高基因傳遞效率和在核准的基因療法中的廣泛應用，在 2024 年佔據市場最大收入佔有率，達到 42.91%。然而，預計在預測期內質體DNA 片段的複合年成長率最快，為 20.13%。
  • 根據開發階段，由於越來越多的基因療法候選藥物進入臨床試驗，預計臨床實驗藥物將在 2024 年佔據最大的市場佔有率。另一方面，臨床前階段藥物預計在預測期內將呈現最快的複合年成長率。
  • 根據應用，腫瘤學領域預計將在 2024 年佔據最大的收益佔有率，並在預測期內以最快的複合年成長率成長。這是由於癌症發生率不斷上升、臨床研發管線不斷健全以及針對各種腫瘤類型的基因療法日益普及。然而，預計遺傳疾病領域在預測期內將以複合年成長率大幅成長。
  • 根據最終用途，生物製藥和製藥公司部門在 2024 年收益佔有率，這得益於對基因治療研發、內部製造能力和戰略夥伴關係關係的投資不斷增加，以加速治療發展。另一方面，預計 CRO/CMO 部門在預測期內將實現最快的複合年成長率。
  • 由於強大的研發投入、先進的製造能力以及產業領袖的集中，北美在 2024 年的收入佔有率方面佔據市場主導地位。預計在預測期內亞太地區將以最快的複合年成長率成長。

目錄

第1章 分析方法與範圍

第2章執行摘要

3. 基因治療起始材料市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 基因治療起始材料市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL分析
    • COVID-19影響分析

第4章基因治療起始材料市場：按產品分類的估計和趨勢分析

  • 特定於產品的儀表板
  • 全球基因療法起始材料市場：按產品進行的差異分析
  • 全球基因療法起始材料市場：按產品分類的市場規模預測和趨勢分析（2018-2030）
  • 病毒載體
    • 病毒載體市場規模、預測與趨勢分析（2018-2030）
    • 腺病毒
    • 逆轉錄病毒
    • 腺結合病毒（AAV）
    • 慢病毒
    • 其他
  • 質體DNA
    • 2018-2030年質體DNA市場規模、預測及趨勢分析
  • 細胞株
    • 2018-2030年細胞株市場規模、預測與趨勢分析
  • 其他
    • 2018-2030年其他市場規模、預測與趨勢分析

第5章基因治療起始材料市場：依發展階段的估計與趨勢分析

  • 每個開發階段的儀表板
  • 全球基因治療起始材料市場：依發展階段變化分析
  • 全球基因療法起始材料市場：按發展階段分類的市場規模預測和趨勢分析（2018-2030）
  • 臨床前階段藥物
    • 臨床前治療：市場規模預測與趨勢分析（2018-2030）
  • 臨床實驗藥物
    • 臨床實驗試驗藥物：市場規模預測與趨勢分析（2018-2030）
  • 非處方藥
    • 非處方藥：市場規模預測與趨勢分析（2018-2030）

第6章基因治療起始材料市場：按應用的估計和趨勢分析

  • 用於特定目的的儀表板
  • 全球基因治療起始材料市場：依應用進行變異分析
  • 全球基因治療起始材料市場：市場規模預測與應用趨勢分析（2018-2030）
  • 瘤
    • 腫瘤學：市場規模預測與趨勢分析（2018-2030）
  • 感染疾病
    • 感染疾病：市場規模預測與趨勢分析（2018-2030）
  • 遺傳性疾病
  • 其他
    • 其他：市場規模預測及趨勢分析（2018-2030年）

第7章基因治療起始材料市場：按最終用途分類的估計和趨勢

  • 按最終用途分類的儀表板
  • 全球基因治療起始材料市場：以最終用途的變化分析
  • 全球基因療法起始材料市場：按最終用途分類的市場規模預測和趨勢分析（2018-2030）
  • 生物製藥和製藥公司
    • 生物製藥和製藥公司：市場規模預測和趨勢分析（2018-2030）
  • 合約研究團隊,合約行銷團隊
    • CRO/CMO：市場規模預測與趨勢分析（2018-2030）
  • 其他
    • 其他：市場規模預測及趨勢分析（2018-2030年）

第8章基因治療起始材料市場：區域估計和趨勢分析

  • 各地區市場佔有率分析（2024 年及 2030 年）
  • 市場儀表板：按地區
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭態勢

  • 參與企業
  • 企業市場分析（2024年）
  • 戰略地圖
  • 參與企業概況
    • 查爾斯河實驗室
    • 賽默飛世爾科技公司
    • 金斯瑞
    • 龍沙
    • 康泰倫特
    • 歐陸科技
    • 丹納赫
    • 默克公司
    • Revvity公司
    • 賽多利斯公司
Product Code: GVR-4-68040-553-8

Gene Therapy Starting Materials Market Growth & Trends:

The global gene therapy starting materials market size is anticipated to reach USD 5.40 billion by 2030 and is projected to grow at a CAGR of 19.24% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is driven by increasing demand for high-quality raw materials to support the expanding pipeline of gene therapies targeting rare and genetic disorders, cancer, and other complex conditions. As more therapies advance through clinical trials and gain regulatory approvals, the need for scalable, GMP-compliant plasmids, viral vectors, and other key inputs continues to rise.

Furthermore, technological advancements, growing R&D investments, and supportive regulatory frameworks are further accelerating the market. In addition, partnerships between biotech firms and manufacturers are enhancing production capabilities and ensuring a consistent supply chain, positioning the gene therapy starting materials industry for strong and sustained growth through the forecast period.

The COVID-19 pandemic further accelerated the demand for gene therapy starting materials by highlighting the need for rapid therapeutic development and scalable manufacturing. It spurred investments in advanced bioproduction infrastructure and increased focus on genetic platforms, driving growth in plasmid DNA, viral vectors, and other critical components used in both vaccine and gene therapy development.

In addition, the expanding pipeline of gene therapies has further fueled market growth. As more therapies advance into clinical trials and receive regulatory approvals, the demand for high-quality starting materials such as plasmid DNA and viral vectors continues to rise. This has prompted increased investments in manufacturing capacity, advanced technologies, and strategic partnerships, enabling efficient scale-up and supply to meet the evolving needs of gene therapy developers worldwide.

However, strict regulatory requirements for safety, quality, and compliance can delay the development and approval of gene therapy products. While essential for ensuring patient safety, these regulations often involve complex documentation, extensive testing, and prolonged review timelines. This can slow market entry, increase operational costs, and create barriers for smaller companies with limited regulatory expertise. As the industry evolves, navigating these requirements remains a critical challenge for stakeholders in the gene therapy starting materials market.

Gene Therapy Starting Materials Market Report Highlights:

  • The viral vectors segment led the market with the largest revenue share of 42.91% in 2024, owing to their high efficiency in gene delivery and widespread use in approved gene therapies. However, the plasmid DNA segment is expected to grow at the fastest CAGR of 20.13% over the forecast period.
  • Based on development stage, the clinical therapeutics segment accounted for the largest market share in 2024, driven by the growing number of gene therapy candidates advancing through clinical trials. On the other hand, the pre-clinical therapeutics segment is expected to witness at the fastest CAGR over the forecast period.
  • Based on application, the oncology segment accounted for the largest revenue share in 2024 and is anticipated to grow at the fastest CAGR over the forecast period, attributed to the rising prevalence of cancer, strong clinical pipeline, and increasing adoption of gene therapies targeting various tumor types. However, the genetic disease segment is projected to grow at a significant CAGR over the forecast period.
  • Based on end use, the biopharmaceutical and pharmaceutical companies segment accounted for the largest market revenue share in 2024, driven by increased investment in gene therapy R&D, in-house manufacturing capabilities, and strategic partnerships to accelerate therapy development. On the other hand, the CROs & CMOs segment is expected to register at the fastest CAGR during the projected period.
  • North America dominated the market with the largest revenue share in 2024 due to strong R&D investment, advanced manufacturing capabilities, and a high concentration of industry leaders. The Asia Pacific region is expected to grow at the fastest CAGR during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Development Stage
    • 1.2.3. Application
    • 1.2.4. End-use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Gene Therapy Starting Materials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising Prevalence of Genetic and Rare Diseases
      • 3.2.1.2. Expanding Pipeline of Gene Therapies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Strict Regulatory Requirements
  • 3.3. Gene Therapy Starting Materials Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Gene Therapy Starting Materials Market: Product Estimates & Trend Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. Global Gene Therapy Starting Materials Market Product Movement Analysis
  • 4.3. Global Gene Therapy Starting Materials Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Viral Vectors
    • 4.4.1. Viral Vectors Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
    • 4.4.2. Adenovirus
      • 4.4.2.1. Adenovirus Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Retrovirus
      • 4.4.3.1. Retrovirus Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 4.4.4. Adeno-Associated Virus (AAV)
      • 4.4.4.1. Adeno-Associated Virus (AAV) Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 4.4.5. Lentivirus
      • 4.4.5.1. Lentivirus Market Estimates and Forecasts, 2018 to 2030 (USD Million)
    • 4.4.6. Others
      • 4.4.6.1. Others Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.5. Plasmid DNA
    • 4.5.1. Plasmid DNA Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 4.6. Cell Lines
    • 4.6.1. Cell Lines Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)

Chapter 5. Gene Therapy Starting Materials Market: Development Stage Estimates & Trend Analysis

  • 5.1. Development Stage Segment Dashboard
  • 5.2. Global Gene Therapy Starting Materials Market Development Stage Movement Analysis
  • 5.3. Global Gene Therapy Starting Materials Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Pre-clinical Therapeutics
    • 5.4.1. Pre-clinical Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 5.5. Clinical Therapeutics
    • 5.5.1. Clinical Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 5.6. Marketed Therapeutics
    • 5.6.1. Marketed Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)

Chapter 6. Gene Therapy Starting Materials Market: Application Estimates & Trend Analysis

  • 6.1. Application Segment Dashboard
  • 6.2. Global Gene Therapy Starting Materials Market Application Movement Analysis
  • 6.3. Global Gene Therapy Starting Materials Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Oncology Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD million)
  • 6.5. Infectious Disease
    • 6.5.1. Infectious Disease Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD million)
  • 6.6. Genetic Disease
    • 6.6.1. Genetic Disease Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD million)

Chapter 7. Gene Therapy Starting Materials Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Segment Dashboard
  • 7.2. Global Gene Therapy Starting Materials Market End Use Movement Analysis
  • 7.3. Global Gene Therapy Starting Materials Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 7.4. Biopharmaceutical & Pharmaceutical Companies
    • 7.4.1. Biopharmaceutical & Pharmaceutical Companies Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 7.5. CROs & CMOs
    • 7.5.1. CROs & CMOs Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
  • 7.6. Other
    • 7.6.1. Other Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)

Chapter 8. Gene Therapy Starting Materials Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Categorization
  • 9.2. Company Market Position Analysis, 2024
  • 9.3. Strategy Mapping
  • 9.4. Participants Overview
    • 9.4.1. Charles River Laboratories
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Thermo Fisher Scientific Inc.
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. GenScript
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Lonza
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Catalent
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Eurofins Scientific
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Danaher
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Merck KGaA
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Revvity, Inc.
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. Sartorius AG
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Gene Therapy Starting Materials Market, by Country, 2018 - 2030 (USD Million)
  • Table 3 North America Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 4 North America Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 5 North America Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 6 North America Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 7 US Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 8 US Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 9 US Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 10 US Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 11 Canada Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 12 Canada Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 13 Canada Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 14 Canada Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 15 Mexico Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 16 Mexico Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 17 Mexico Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 18 Mexico Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 19 Europe Gene Therapy Starting Materials Market, by Country, 2018 - 2030 (USD Million)
  • Table 20 Europe Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 21 Europe Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 22 Europe Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 23 Europe Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 24 UK Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 25 UK Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 26 UK Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 27 UK Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 28 Germany Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 29 Germany Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 30 Germany Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 31 Germany Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 32 Italy Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 33 Italy Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 34 Italy Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 35 Italy Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 36 France Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 37 France Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 38 France Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 39 France Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 40 Spain Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 41 Spain Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 42 Spain Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 43 Spain Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 44 Sweden Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 45 Sweden Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 46 Sweden Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 47 Sweden Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 48 Denmark Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 49 Denmark Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 50 Denmark Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 51 Denmark Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 52 Norway Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 53 Norway Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 54 Norway Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 55 Norway Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific Gene Therapy Starting Materials Market, by Country, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 61 China Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 62 China Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 63 China Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 64 China Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 65 Japan Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 66 Japan Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 67 Japan Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 68 Japan Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 69 India Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 70 India Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 71 India Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 72 India Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 73 South Korea Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 74 South Korea Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 75 South Korea Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 76 South Korea Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 77 Australia Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 78 Australia Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 79 Australia Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 80 Australia Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 81 Thailand Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 82 Thailand Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 83 Thailand Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 84 Thailand Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 85 Latin America Gene Therapy Starting Materials Market, by Country, 2018 - 2030 (USD Million)
  • Table 86 Latin America Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 87 Latin America Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 88 Latin America Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 89 Latin America Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 90 Brazil Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 91 Brazil Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 92 Brazil Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 93 Brazil Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 94 Argentina Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 95 Argentina Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 96 Argentina Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 97 Argentina Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 98 Middle East Africa Gene Therapy Starting Materials Market, by Country, 2018 - 2030 (USD Million)
  • Table 99 Middle East Africa Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 100 Middle East Africa Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 101 Middle East Africa Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 102 Middle East Africa Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 103 South Africa Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 104 South Africa Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 105 South Africa Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 106 South Africa Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 111 UAE Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 112 UAE Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 113 UAE Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 114 UAE Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)
  • Table 115 Kuwait Gene Therapy Starting Materials Market, by Product, 2018 - 2030 (USD Million)
  • Table 116 Kuwait Gene Therapy Starting Materials Market, by Development Stage, 2018 - 2030 (USD Million)
  • Table 117 Kuwait Gene Therapy Starting Materials Market, by Application, 2018 - 2030 (USD Million)
  • Table 118 Kuwait Gene Therapy Starting Materials Market, by End-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Data Triangulation Techniques
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Market formulation & Validation
  • Fig. 6 Gene Therapy Starting Materials Market: Market Outlook
  • Fig. 7 Parent Market Outlook
  • Fig. 8 Related/Ancillary Market Outlook
  • Fig. 9 Gene Therapy Starting Materials Market Driver Impact
  • Fig. 10 Gene Therapy Starting Materials Market Restraint Impact
  • Fig. 11 Gene Therapy Starting Materials Market Strategic Initiatives Analysis
  • Fig. 12 Gene Therapy Starting Materials Market: Product Movement Analysis
  • Fig. 13 Gene Therapy Starting Materials Market: Product Outlook and Key Takeaways
  • Fig. 14 Viral Vectors Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Adenovirus Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Retrovirus Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Adeno-Associated Virus (AAV) Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Lentivirus Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Others Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Cell Lines Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Plasmid DNA Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Others Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Gene Therapy Starting Materials Market: Development Stage Movement Analysis
  • Fig. 24 Gene Therapy Starting Materials Market: Development Stage Outlook and Key Takeaways
  • Fig. 25 Pre-clinical Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Clinical Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Marketed Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Gene Therapy Starting Materials Market: Application Movement Analysis
  • Fig. 29 Gene Therapy Starting Materials Market: Application Outlook and Key Takeaways
  • Fig. 30 Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Infectious Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Genetic Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Other Disease Diagnostic Applications Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Gene Therapy Starting Materials Market: End-Use Movement Analysis
  • Fig. 37 Gene Therapy Starting Materials Market: End-Use Outlook and Key Takeaways
  • Fig. 38 Biopharmaceutical & Pharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 CROs & CMOs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Global Gene Therapy Starting Materials Market: Regional Movement Analysis
  • Fig. 42 Global Gene Therapy Starting Materials Market: Regional Outlook and Key Takeaways
  • Fig. 43 North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 US Country Dynamics
  • Fig. 45 US Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Canada Country Dynamics
  • Fig. 47 Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Mexico Country Dynamics
  • Fig. 49 Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 UK Country Dynamics
  • Fig. 52 UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Germany Country Dynamics
  • Fig. 54 Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 France Country Dynamics
  • Fig. 56 France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Italy Country Dynamics
  • Fig. 58 Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Spain Country Dynamics
  • Fig. 60 Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Denmark Country Dynamics
  • Fig. 62 Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Sweden Country Dynamics
  • Fig. 64 Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Norway Country Dynamics
  • Fig. 66 Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 China Country Dynamics
  • Fig. 69 China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Japan Country Dynamics
  • Fig. 71 Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 India Country Dynamics
  • Fig. 73 India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Thailand Country Dynamics
  • Fig. 75 Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 South Korea Country Dynamics
  • Fig. 77 South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Australia Country Dynamics
  • Fig. 79 Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Brazil Country Dynamics
  • Fig. 82 Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Argentina Country Dynamics
  • Fig. 84 Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Middle East and Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 South Africa Country Dynamics
  • Fig. 87 South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Saudi Arabia Country Dynamics
  • Fig. 89 Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 UAE Country Dynamics
  • Fig. 91 UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Kuwait Country Dynamics
  • Fig. 93 Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Market Position of Key Market Players